The Rosen Law Firm, P.A. announces that it is investigating the Board of Directors of Durata Therapeutics, Inc. (NASDAQ:DRTX) for possible breaches of fiduciary duty and other violations of law by failing to adequately shop Durata to maximize shareholder value before agreeing to be acquired by Actavis plc (NYSE:ACT) .

Under the terms of the proposed transaction, shareholders will receive $23.00 in cash and the right to receive an additional payment of up to $5.00 per share, if certain goals are reached, for each share of Durata they own. The proposed transaction is valued at approximately $675 million. The investigation relates to whether the proposal for $23.00 in cash and the right to receive an additional payment of up to $5.00 per share is fair to public shareholders and whether Durata’s Board breached its fiduciary duties in connection with the proposed sale.

Risk Disclosure: Finances.com will not accept any liability for loss or damage as
a result of reliance on the information contained within this website including
data, quotes, charts and buy/sell signals. Please be fully informed regarding the
risks and costs associated with trading the financial markets, it is one of the
riskiest investment forms possible. Currency trading on margin involves high
risk, and is not suitable for all investors. Before deciding to trade foreign
exchange or any other financial instrument you should carefully consider your
investment objectives, level of experience, and risk appetite.